Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

AbbVie (ABBV) recently submitted a Supplemental New Drug Application to the FDA for a new combination regimen targeting chronic lymphocytic leukemia, which accompanies positive Phase 3 trial ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...

A Delaware jury has ruled that Revance infringed three patents on AbbVie's Botox and has awarded a royalty payment of $56 million.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how positive Phase III results for Emrelis may position AbbVie as a key player in MET-high non-small cell lung cancer, ...

AbbVie Inc. (ABBV) has emerged as a strong performer in financial and technical terms, attracting investor attention due to its long-term growth potential. With consistent revenue generation and ...

AbbVie's pair of immunology drugs is expected to help drive growth into the next decade. The company should successfully improve its lineup thanks to its deep pipeline. AbbVie can overcome tariff ...

Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal worth about $1 billion, Bloomberg News reported on Wednesday, citing ...

AbbVie is in talks to acquire mental health therapeutics company Gilgamesh Pharmaceuticals in a deal highlighting growing takeover interest in the sector, according to people familiar with the matter.